Bob Josefsberg
Corporate Officer/Principal bei Chamberlain Healthcare Public Relations
Profil
Bob Josefsberg is currently working as the Executive Vice President at Chamberlain Healthcare Public Relations.
Prior to this, he worked as the Head-Media at Karuna Therapeutics, Inc.
Aktive Positionen von Bob Josefsberg
| Unternehmen | Position | Beginn |
|---|---|---|
Chamberlain Healthcare Public Relations
 Chamberlain Healthcare Public Relations Miscellaneous Commercial ServicesCommercial Services Chamberlain Healthcare Public Relations provides public relations services to the healthcare industry. It offers data strategy and communications; message and content development; advocacy relations; consumer media campaigns; traditional and social media; spokesperson recruitment and management; issues and crisis management and national and grassroots programming. The company is headquartered in New York, NY. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Bob Josefsberg
| Unternehmen | Position | Ende |
|---|---|---|
| KARA THER | Public Communications Contact | 18.03.2024 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Chamberlain Healthcare Public Relations
Chamberlain Healthcare Public Relations Miscellaneous Commercial ServicesCommercial Services Chamberlain Healthcare Public Relations provides public relations services to the healthcare industry. It offers data strategy and communications; message and content development; advocacy relations; consumer media campaigns; traditional and social media; spokesperson recruitment and management; issues and crisis management and national and grassroots programming. The company is headquartered in New York, NY. | Commercial Services |
Karuna Therapeutics, Inc.
 Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. | Health Technology |
